4172 Stock Overview
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
InnoPharmax Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$15.05 |
| 52 Week High | NT$34.00 |
| 52 Week Low | NT$14.70 |
| Beta | 0.68 |
| 1 Month Change | -1.95% |
| 3 Month Change | -16.39% |
| 1 Year Change | -17.98% |
| 3 Year Change | -6.81% |
| 5 Year Change | 64.48% |
| Change since IPO | -58.19% |
Recent News & Updates
Shareholder Returns
| 4172 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -2.0% | -5.4% | -2.1% |
| 1Y | -18.0% | 3.0% | 27.5% |
Return vs Industry: 4172 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 4172 underperformed the TW Market which returned 27.5% over the past year.
Price Volatility
| 4172 volatility | |
|---|---|
| 4172 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4172's share price has been volatile over the past 3 months.
Volatility Over Time: 4172's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 33 | n/a | www.innopharmax.com |
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company’s core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases.
InnoPharmax Inc. Fundamentals Summary
| 4172 fundamental statistics | |
|---|---|
| Market cap | NT$1.43b |
| Earnings (TTM) | -NT$84.17m |
| Revenue (TTM) | NT$49.10m |
29.1x
P/S Ratio-17.0x
P/E RatioIs 4172 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4172 income statement (TTM) | |
|---|---|
| Revenue | NT$49.10m |
| Cost of Revenue | NT$38.01m |
| Gross Profit | NT$11.08m |
| Other Expenses | NT$95.25m |
| Earnings | -NT$84.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 22.57% |
| Net Profit Margin | -171.44% |
| Debt/Equity Ratio | 0% |
How did 4172 perform over the long term?
See historical performance and comparison